Unknown

Dataset Information

0

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.


ABSTRACT: History of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses circulating from 1968 to 2018. We found that vaccination and infection elicited cross-reactive antibody responses, predominantly directed against newer or future strains. Childhood H3-priming increased the breadth and magnitude of back-boosted A/H3N2-specific antibodies in adults. Broader and more durable A/H3N2-specific antibodies were observed in repeatedly vaccinated adults than in children and previously unvaccinated adults. Our findings suggest that early A/H3N2 exposure and frequent seasonal vaccination could increase the breadth and seropositivity of antibody responses, which may improve vaccine protection against future viruses.

SUBMITTER: Ertesvag NU 

PROVIDER: S-EPMC9232600 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses.

Ertesvåg Nina Urke NU   Cox Rebecca Jane RJ   Lartey Sarah Larteley SL   Mohn Kristin G-I KG   Brokstad Karl Albert KA   Trieu Mai-Chi MC  

NPJ vaccines 20220624 1


History of influenza A/H3N2 exposure, especially childhood infection, shape antibody responses after influenza vaccination and infection, but have not been extensively studied. We investigated the breadth and durability of influenza A/H3N2-specific hemagglutinin-inhibition antibodies after live-attenuated influenza vaccine in children (aged 3-17 years, n = 42), and after inactivated influenza vaccine or infection in adults (aged 22-61 years, n = 42) using 14 antigenically distinct A/H3N2 viruses  ...[more]

Similar Datasets

| S-EPMC8974393 | biostudies-literature
| S-EPMC5215349 | biostudies-literature
| S-EPMC4943536 | biostudies-literature
| S-EPMC4054433 | biostudies-literature
| S-EPMC3405050 | biostudies-other
| S-EPMC4941553 | biostudies-literature
| S-EPMC8200319 | biostudies-literature
| S-EPMC6358683 | biostudies-literature
| S-EPMC3251064 | biostudies-literature
| S-EPMC5604745 | biostudies-literature